Research advances in estrogen receptor low positive early breast cancer
Endocrine therapy is the most important adjuvant treatment for early estrogen receptor (ER)-positive breast cancer. ER-low-positive (immunohistochemistry staining 1%-10%) breast cancer has drawn widespread attention in recent years. This group accounts for 3%-9% of overall breast cancer patients. Th...
Saved in:
Main Author: | JIN Yizi, LIN Mingxi, ZENG Cheng, GUO Qing, ZHANG Jian |
---|---|
Format: | Article |
Language: | English |
Published: |
Editorial Office of China Oncology
2024-10-01
|
Series: | Zhongguo aizheng zazhi |
Subjects: | |
Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/1732079468748-208740238.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Annotation-free deep learning algorithm trained on hematoxylin & eosin images predicts epithelial-to-mesenchymal transition phenotype and endocrine response in estrogen receptor-positive breast cancer
by: Kaimin Hu, et al.
Published: (2025-01-01) -
Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast Cancer
by: Murugesan Palaniappan
Published: (2024-11-01) -
In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach
by: Gabriele La Monica, et al.
Published: (2024-12-01) -
Case report: Prolonged benefit of ESG401, a Trop2 antibody-drug conjugate, in endocrine-refractory hormone receptor-positive, HER-2 negative metastatic breast cancer
by: Jing Zhao, et al.
Published: (2024-11-01) -
Comprehensive review of breast cancer risk factors, diagnosis, screening, and treatment methods
by: Nurjamal Hoque, et al.
Published: (2024-10-01)